{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Aquestive Therapeutics, Inc.
Aquestive Therapeutics Hits New 52-Week High of $7.50, Up 165.94%
Aquestive Therapeutics, Inc. achieved a new 52-week high of USD 7.50 on October 15, 2025, reflecting a significant increase from its previous low. With a market capitalization of USD 606 million, the company has shown strong financial metrics despite being loss-making and having a unique debt-to-equity ratio.
Aquestive Therapeutics Hits New 52-Week High of $6.97, Up 149%
Aquestive Therapeutics, Inc. has achieved a new 52-week high of USD 6.97, reflecting a significant increase from its previous low of USD 2.12. With a market capitalization of USD 606 million, the company has shown strong financial metrics despite being loss-making and having a negative debt-to-equity ratio.
Aquestive Therapeutics Hits New 52-Week High of $6.43
Aquestive Therapeutics, Inc. has achieved a new 52-week high, reflecting a significant increase from its previous low and showcasing a strong one-year performance compared to the S&P 500. With a market capitalization of USD 606 million, the company exhibits impressive financial metrics despite currently being loss-making.
Aquestive Therapeutics Hits New 52-Week High of $6.00, Up 105.43%
Aquestive Therapeutics, Inc. has achieved a new 52-week high, reflecting a significant increase from its previous low and showcasing a strong one-year performance. With a market capitalization of USD 606 million, the company demonstrates effective equity management despite being loss-making and facing challenges in asset valuation.
Is Aquestive Therapeutics, Inc. technically bullish or bearish?
As of September 4, 2025, Aquestive Therapeutics, Inc. is in a bullish trend with strong moving averages and MACD indicators, despite a bearish weekly RSI, and has outperformed the S&P 500 with a year-to-date return of 38.76%.
Is Aquestive Therapeutics, Inc. technically bullish or bearish?
As of June 11, 2025, the market trend is mildly bearish, driven by daily moving averages and monthly MACD signals, despite some mixed bullish indicators on the weekly timeframe.
Who are in the management team of Aquestive Therapeutics, Inc.?
As of March 2022, the management team of Aquestive Therapeutics, Inc. includes Mr. Santo Costa (Independent Chairman), Mr. Keith Kendall (CEO), Mr. John Cochran (Vice Chairman), and several independent directors: Mr. Douglas Bratton, Dr. Gregory Brown, Ms. Nancy Lurker, and Mr. James Scibetta. They oversee the company's strategic direction and operations.
What does Aquestive Therapeutics, Inc. do?
Aquestive Therapeutics, Inc. is a specialty pharmaceutical company focused on CNS disease treatments, with a market cap of $332.75 million and recent net sales of $9 million, but a net loss of $23 million. The company has no dividend yield and a negative price-to-book ratio.
How big is Aquestive Therapeutics, Inc.?
As of Jun 18, Aquestive Therapeutics, Inc. has a market capitalization of 332.75 million and reported net sales of 54.23 million with a net profit of -54.24 million over the latest four quarters. The company's balance sheet shows shareholder's funds of -60.16 million and total assets of 101.42 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
